Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 650 JPY 0.67% Market Closed
Market Cap: 1.3T JPY
Have any thoughts about
Eisai Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Eisai Co Ltd stock under the Base Case scenario is 7 322.83 JPY. Compared to the current market price of 4 650 JPY, Eisai Co Ltd is Undervalued by 36%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
7 322.83 JPY
Undervaluation 36%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eisai Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Eisai Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Eisai Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Eisai Co Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Eisai Co Ltd

Provide an overview of the primary business activities
of Eisai Co Ltd.

What unique competitive advantages
does Eisai Co Ltd hold over its rivals?

What risks and challenges
does Eisai Co Ltd face in the near future?

Summarize the latest earnings call
of Eisai Co Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Eisai Co Ltd.

Provide P/S
for Eisai Co Ltd.

Provide P/E
for Eisai Co Ltd.

Provide P/OCF
for Eisai Co Ltd.

Provide P/FCFE
for Eisai Co Ltd.

Provide P/B
for Eisai Co Ltd.

Provide EV/S
for Eisai Co Ltd.

Provide EV/GP
for Eisai Co Ltd.

Provide EV/EBITDA
for Eisai Co Ltd.

Provide EV/EBIT
for Eisai Co Ltd.

Provide EV/OCF
for Eisai Co Ltd.

Provide EV/FCFF
for Eisai Co Ltd.

Provide EV/IC
for Eisai Co Ltd.

Show me price targets
for Eisai Co Ltd made by professional analysts.

What are the Revenue projections
for Eisai Co Ltd?

How accurate were the past Revenue estimates
for Eisai Co Ltd?

What are the Net Income projections
for Eisai Co Ltd?

How accurate were the past Net Income estimates
for Eisai Co Ltd?

What are the EPS projections
for Eisai Co Ltd?

How accurate were the past EPS estimates
for Eisai Co Ltd?

What are the EBIT projections
for Eisai Co Ltd?

How accurate were the past EBIT estimates
for Eisai Co Ltd?

Compare the revenue forecasts
for Eisai Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Eisai Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Eisai Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Eisai Co Ltd compared to its peers.

Compare the P/E ratios
of Eisai Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Eisai Co Ltd with its peers.

Analyze the financial leverage
of Eisai Co Ltd compared to its main competitors.

Show all profitability ratios
for Eisai Co Ltd.

Provide ROE
for Eisai Co Ltd.

Provide ROA
for Eisai Co Ltd.

Provide ROIC
for Eisai Co Ltd.

Provide ROCE
for Eisai Co Ltd.

Provide Gross Margin
for Eisai Co Ltd.

Provide Operating Margin
for Eisai Co Ltd.

Provide Net Margin
for Eisai Co Ltd.

Provide FCF Margin
for Eisai Co Ltd.

Show all solvency ratios
for Eisai Co Ltd.

Provide D/E Ratio
for Eisai Co Ltd.

Provide D/A Ratio
for Eisai Co Ltd.

Provide Interest Coverage Ratio
for Eisai Co Ltd.

Provide Altman Z-Score Ratio
for Eisai Co Ltd.

Provide Quick Ratio
for Eisai Co Ltd.

Provide Current Ratio
for Eisai Co Ltd.

Provide Cash Ratio
for Eisai Co Ltd.

What is the historical Revenue growth
over the last 5 years for Eisai Co Ltd?

What is the historical Net Income growth
over the last 5 years for Eisai Co Ltd?

What is the current Free Cash Flow
of Eisai Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Eisai Co Ltd.

Business Breakdown

Eisai Co., Ltd., founded in 1941 and headquartered in Tokyo, Japan, stands as a prominent global player in the pharmaceutical industry, dedicated to research and development in areas such as neurology and oncology. With a mission encapsulated in their philosophy of "human health care" (hhc), Eisai strives not only for profit but also for the well-being of patients, positioning itself as a company that deeply values purpose alongside its financial goals. Over the years, Eisai has gained recognition for its innovative products, particularly the Alzheimer's treatment, Aricept, which has generated a substantial portion of its revenue. Investors might find this focus on neurodegenerative diseases...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Eisai Co Ltd

Current Assets 733.2B
Cash & Short-Term Investments 304.9B
Receivables 205.4B
Other Current Assets 223B
Non-Current Assets 687B
Long-Term Investments 59.6B
PP&E 165.4B
Intangibles 334.3B
Other Non-Current Assets 127.8B
Current Liabilities 311B
Accounts Payable 77.8B
Other Current Liabilities 233.2B
Non-Current Liabilities 213.5B
Long-Term Debt 134.8B
Other Non-Current Liabilities 78.7B
Efficiency

Earnings Waterfall
Eisai Co Ltd

Revenue
733.8B JPY
Cost of Revenue
-151.2B JPY
Gross Profit
582.7B JPY
Operating Expenses
-541.9B JPY
Operating Income
40.8B JPY
Other Expenses
-8.1B JPY
Net Income
32.6B JPY

Free Cash Flow Analysis
Eisai Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Eisai reported a Q2 FY2024 revenue increase of 3% year-on-year, totaling JPY 385 billion, driven primarily by a 5% growth in the pharmaceutical segment, notably from LEQEMBI, which saw a JPY 15.9 billion rise. However, operating profit declined to JPY 27.8 billion (down 13%), with SG&A costs up due to market expansion efforts. LEQEMBI aims for U.S. profitability by FY2026, while Japan and China expect breakeven in FY2025. Total annual revenues are projected at JPY 42.5 billion, highlighting the challenge of managing infusion capacity against rising demand.

What is Earnings Call?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Eisai Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
50/100
Profitability
Score

Eisai Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Eisai Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
Long-Term Solvency
Negative Net Debt
82/100
Solvency
Score

Eisai Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Eisai Co Ltd

Wall Street analysts forecast Eisai Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Eisai Co Ltd is 7 242.36 JPY with a low forecast of 4 646 JPY and a high forecast of 10 185 JPY.

Lowest
Price Target
4 646 JPY
0% Downside
Average
Price Target
7 242.36 JPY
56% Upside
Highest
Price Target
10 185 JPY
119% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Eisai Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Eisai Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

News

Other Videos

Profile

Eisai Co Ltd Logo
Eisai Co Ltd

Country

Japan

Industry

Pharmaceuticals

Market Cap

1.3T JPY

Dividend Yield

3.44%

Description

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. The company is headquartered in Bunkyo-Ku, Tokyo-To and currently employs 11,237 full-time employees. The firm operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The firm is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Contact

TOKYO-TO
Bunkyo-ku
Eisai Main Bldg., 4-6-10, Koishikawa
+81338173700.0
www.eisai.co.jp

IPO

1961-09-14

Employees

11 237

Officers

CEO, Representative Corporate Officer & Director
Mr. Haruo Naito
Senior VP & President of EMEA Region
Mr. Gary Hendler
VP & Chief Clinical Officer
Dr. Lynn D. Kramer FAAN, M.D.
Senior Vice President
Ms. Yanhui Feng
VP & CFO
Mitsuru Shomon
Representative Corporate Officer, EVP, COO & Chief Growth Officer
Mr. Keisuke Naito
Show More
VP & Chief Information Officer
Makoto Hoketsu
Senior VP, Chief Government Relations Officer & Chief IR Officer
Mr. Masatomi Akana
VP, General Counsel & Chief Compliance Officer
Shin Kato
Vice President of Corporate Communications & Sustainability
Ms. Sayoko Sasaki
Show Less

See Also

Discover More
What is the Intrinsic Value of one Eisai Co Ltd stock?

The intrinsic value of one Eisai Co Ltd stock under the Base Case scenario is 7 322.83 JPY.

Is Eisai Co Ltd stock undervalued or overvalued?

Compared to the current market price of 4 650 JPY, Eisai Co Ltd is Undervalued by 36%.

Back to Top